Figure 8.

Inhibition of CXCR2/CXCR2 ligand biology attenuates vascular remodeling and angiogenic activity independent of its effects on neutrophils during murine BOS. (A) FACS analysis of neutrophils in tracheal allografts from recipients treated with anti-CXCR2 compared with control Ab. (B) FACS analysis of neutrophils in tracheal allografts from recipients treated with RB6-8C5 Ab compared with control Ab. *P < 0.05. (C) Representative CMP assay for vascular remodeling of tracheal-derived angiogenic activity from allografts with in vivo–administered RB6-8C5 Ab compared with control Ab at days 7 and 21. Magnification, ×20. (D) FACS analysis of MECA-32 from allografts treated in vivo with RB6-8C5 Ab compared with control Ab.